GleamWall
中文EN

SPRB SPRUCE BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1683553 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-90.2%
TTM net income YoY-21.4%
TTM EPS YoY-55.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-7,100.0%
Net margin-6,869.3%
FCF margin-6,821.8%
EBITDA margin-7,096.4%

Returns

ROE-167.9%
ROA-119.1%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets64.8%
Debt / equity0.10x
Current ratio1.54x
Interest coverage-353.48x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.8%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$4.91M
R&D expense$19.52M$46.42M
SG&A expense$16.99M$14.64M
Operating income-$36.51M-$56.15M
Interest expense$90,000$307,000
Income tax$0$0
Net income-$38.97M-$53.04M
EBITDA-$36.49M-$56.10M
EPS (basic)-50.83-96.40
EPS (diluted)-50.83-96.40
Weighted avg. shares (diluted)766,598550,146
Balance sheet
Cash & equivalents$48.91M$38.79M
Current assets$52.11M$44.21M
Total assets$53.02M$45.21M
Current liabilities$10.09M$15.25M
Short-term debt$0$1.62M
Long-term debt$0$124,000
Total debt$0$1.75M
Total liabilities$10.51M$16.39M
Shareholders' equity$42.52M$28.82M
Net debt-$48.91M-$37.04M
Shares outstanding1.37M563,042
Cash flow statement
Operating cash flow-$33.33M-$55.96M
Capital expenditure—$0
Free cash flow—-$55.96M
Investing cash flow—$0
Financing cash flow$43.48M-$1.62M
Depreciation & amortization$21,000$46,000
Stock-based compensation$2.57M$5.35M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.